Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

Neuromuscular Diseases: Myasthenia Gravis, Spinal Muscular Atrophy, Nondystrophic Myotonias, and Muscular Dystrophies 

Neuromuscular Diseases: Myasthenia Gravis, Spinal Muscular Atrophy, Nondystrophic Myotonias, and Muscular Dystrophies
Chapter:
Neuromuscular Diseases: Myasthenia Gravis, Spinal Muscular Atrophy, Nondystrophic Myotonias, and Muscular Dystrophies
Author(s):

Johanna Hamel

, and Emma Ciafaloni

DOI:
10.1093/med/9780190667351.003.0024
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 05 August 2020

Myasthenia gravis is an acquired autoimmune disorder characterized by weakness of skeletal muscle, which often affects women in the childbearing age. A number of questions arise when a woman with myasthenia gravis plans to become pregnant or presents with pregnancy, as myasthenia can affect the pregnancy, delivery and the fetus. In addition, the pregnancy can affect the course of myasthenia and worsening of the disease during pregnancy may require treatment modifications. Therefore supportive counseling, ideally preceding conception, is indicated, focusing on issues of fertility, treatment optimization and drug safety, risks of worsening of symptoms during pregnancy and delivery. Counseling on possible effects on the infant should be discussed, as such as neonatal myasthenia gravis, a treatable and transient disease. Patients with myasthenia gravis may require more intensive monitoring and care, and should be supported by a multidisciplinary team involving the obstetrician, anesthesiologist, and neurologist.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.